Social Security Works

Comments on NIH Prospective Exclusive License on Diabetes Treatments

Posted on by Claire Cassedy

Update. NIH sent us a 147 word response on November 23, 2018: NIH to KEI regarding Ovensa 23 NOV 2018. The brief reply states that “Prior to posting notices of a proposed grant of exclusive commercialization licenses, the NIH determines… Continue Reading →

2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Posted on by James Love

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading →